OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation

Transplant International

Volumn 18, Issue 7, 2005, Pages 835-843

  Barkholt, Lisbeth ^a,c   Linde, Annika ^a,b   Falk, Kerstin I ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Epstein Barr virus; Ganciclovir; Liver transplantation; Lymphoma; OKT3; Real time PCR

Indexed keywords

CYCLOSPORIN A; GANCICLOVIR; OKT 3; TACROLIMUS; VIRUS DNA; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA DETERMINATION; EPSTEIN BARR VIRUS; FEMALE; HEPATITIS; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; LYMPHOMA; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIREMIA; VIRUS INFECTION; VIRUS LOAD; BLOOD; DRUG ANTAGONISM; GENE DOSAGE; GENETICS; MIDDLE AGED; POSTOPERATIVE PERIOD; VIROLOGY; VIRUS GENOME; VIRUS HEPATITIS;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GANCICLOVIR; GENE DOSAGE; GENOME, VIRAL; HEPATITIS, VIRAL, HUMAN; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LYMPHOMA; MALE; MIDDLE AGED; MUROMONAB-CD3; POSTOPERATIVE PERIOD; TACROLIMUS; VIRAL LOAD; VIREMIA;

EID: 26044445253     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00145.x     Document Type: Article

References (43)

1. Zingg W, Bossart W, Berli E, Nedal D. Detection and quantification of cell-free Epstein-Barr virus by polymerase chain reaction and subsequent DNA enzyme immunoassay. J Virol Methods 1999; 79: 141.
2. Limaye AP, Huang ML, Atienza EE, Ferrenberg JM, Corey L. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. J Clin Microbiol 1999; 37: 1113.
3. Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000; 38: 712.
4. Lo YM, Chan LY, Chan AT, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999; 59: 5452.
5. Gan YJ, Sullivan JL, Sixby JW. Detection of cell-free Epstein-Barr virus DNA in serum during acute infectious mononucleosis. J Infect Dis 1994; 170: 436.
6. Borysiewicz LK, Haworth SJ, Cohen J, Mundin J, Rickinson A, Sissons JG. Epstein-Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis. Q J Med 1986; 58: 111.
7. Hanto DW, Sakamoto K, Purtilo DT, et al. The Epstein-Barr virus in the pathogenesis of post-transplant lymphoproliferative disorders. Clinical, pathologic, and virologic correlation. Surgery 1981; 90: 204.
8. Craig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol 1993; 99: 265.
9. Gross TG, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251.
10. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 1999; 68: 1517.
11. Preiksaitis JK, Diaz-Mitoma R, Mirzayans F, Roberts S, Tyrell DLJ. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 1992; 166: 986.
12. Nalesnik MA. Clinical and pathologic features of posttransplant- transplant lymphoproliferative disorders (PTLD). Springer Semin Immunopathol 1998; 20: 325.
13. Jain A, Nalesnik M, Reyes J, et al. Posttransplant lymphoproliferative disorders in liver transplantation. A 20-years experience. Ann Surg 2002; 236: 429.
14. Duvoux C, Pageaux GP, Vanlemmens C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002; 74: 1103.
15. Barkholt L, Reinholt F, Teramoto N, Enbom M, Dahl H, Linde A. Polymerase chain reaction and in situ hybridization of Epstein-Barr virus (EBV) in liver biopsy specimens facilitate the diagnosis of EBV hepatitis after liver transplantation. Transpl Int 1998; 11: 336.
16. Ericzon BG, Eusufzai S, Soderdahl G, Duraj F, Einarsson K, Angelin B. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. Transplantation 1997; 63: 74.
17. Enbom M, Strand A, Falk KI, Linde A. Detection of Epstein-Barr virus, but not human herpesvirus 8, DNA in cervical secretions from Swedish women by real-time polymerase chain reaction. Sex Transm Dis 2001; 28: 300.
18. Linde A, Andersson J, Lundgren G, Wahren B. Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infection. J Med Virol 1987; 21: 109.
19. Brytting M, Mousavi-Jazi M, Bostrom L, et al. Cytomegalovirus DNA in peripheral blood leukocytes and plasma from bone marrow transplant recipients. Transplantation 1995; 60: 961.
20. Ljungman P, Lore K, Aschan J, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 583.
21. Cen H, Breinig MC, Atchison RW, Ho M, McKnight LC. Epstein-Barr virus transmission via donor organ. J Virol 1991; 65: 976.
22. Chadburn A, Cesarman E, Knowles D. Molecular pathology of posttransplant lymphoproliferative disorders. Semin Diagn Pathol 1997; 14: 15.
23. Green M, Bueno J, Rowe D, et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000; 70: 593.
24. Finn L, Reyes J, Bueno J, Yunis E. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 1998; 22: 299.
25. Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124: 1242.
26. Telenti A, Smith TF, Ludwig J, Keating MR, Krom RA, Wiesner RH. Epstein-Barr virus and persistent graft dysfuntion after liver transplantation. Hepatology 1991; 14: 282.
27. Mutimer D, Kaur N, Tang H, et al. Quatitation of Epstein-Barr virus DNA in the blood of adult liver transplant recipients. Transplantation 2000; 69: 954.
28. Neuhaus P, Klupp J, Langrehr JM, et al. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial. Transplantation 2000; 69: 2343.
29. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232: 490.
30. Smets F, Latine D, Bazin H, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002; 73: 1603.
31. Van Esser JWJ, Niesters HGM, Thijsen SFT, et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001; 113: 814.
32. Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpes viruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158: 124.
33. Barkholt L, Ericzon B-G, Tollemar J, et al. Infections in human liver recipients: different patterns early and late after transplantation. Transpl Int 1993; 6: 77.
34. Cockfild SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 3: 70-78, 2001.
35. Hanto DW, Frizzera G, Gajl-Peczalska J, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306: 913.
36. Hanto DW, Frizzera G, Gajl-Peczalska J, et al. Acyclovir-therapy of Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplant Proc 1985; 17: 89.
37. Pirsch JD, Stratta RJ, Sollinger HW, et al. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989; 86: 241.
38. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001; 3: 79.
39. Andersson J. An overview of Epstein-Barr virus: from discovery to future directions for treatment and prevention. Herpes 2000; 7: 76.
40. Davis CL. The antiviral prophylaxis of post-transplant lymphoproliferative disorder. Springer Semin Immunopathol 1998; 20: 437.
41. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604.
42. Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999; 68: 997.
43. Srivastava T, Zwick DL, Rothberg PG, Warady BA. Posttransplant lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol 1999; 13: 748.